Ionis Pharmaceuticals IONS Current Income Tax Expense Benefit Utilization Of State Tax Loss Carryforwards
Current Income Tax Expense Benefit Utilization Of State Tax Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:CurrentIncomeTaxExpenseBenefitUtilizationOfStateTaxLossCarryforwards.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's current income tax expense benefit utilization of state tax loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's current income tax expense benefit utilization of state tax loss carryforwards?
- Ionis Pharmaceuticals (IONS) reported current income tax expense benefit utilization of state tax loss carryforwards of -$800K in Q4 2023.
- What does current income tax expense benefit utilization of state tax loss carryforwards mean?
- The tax savings from using past state-level losses to lower current taxes.
- How do you interpret current income tax expense benefit utilization of state tax loss carryforwards?
- Higher utilization indicates the company is successfully offsetting current tax liabilities with historical losses.
- How does current income tax expense benefit utilization of state tax loss carryforwards compare across companies?
- Standard for companies transitioning from loss-making to profitable status.